Supplement for FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis
Published: 7 November 2024| Version 1 | DOI: 10.17632/23tcsdt2hc.1
Contributors:
, , , , , , , , , , , Description
Supplemental material in support of the article "FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis"
Files
Categories
Dermatology
Funding
Janssen Research and Development